Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. - Wikidata - wikimedia - TriplyDB

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.

http://www.wikidata.org/entity/Q40326178

about

Systemic therapy of Cushing's syndrome Treatment of Cushing disease: overview and recent findings Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.Clinical use of pasireotide for Cushing's disease in adults The Treatment of Cushing's Disease.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations.Medical treatment of Cushing's disease: Overview and recent findings.Update on medical treatment for Cushing's disease.Pharmacological management of Cushing's syndrome: an update.Treatment Options in Cushing's Disease.Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics Medical management of Cushing's disease: what is the future?Endocrine clinical update: where are we in the therapeutic management of pituitary-dependent hypercortisolism?Drugs in the medical treatment of Cushing's syndrome.Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Establishment of a protocol to extend the lifespan of human hormone-secreting pituitary adenoma cells.Currently used and investigational drugs for Cushing´s disease.Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary.New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.Inhibitory Effects of a Novel PPAR-γ Agonist MEKT1 on Pomc Expression/ACTH Secretion in AtT20 Cells.

P2860

Q22000607-6C94B954-BBD2-49BC-AEA1-DCBB08C0A2B1 Q24626819-61017C82-2501-4AD9-86FF-C785949CBB65 Q24629410-F2B20A5E-AACA-47EC-8BD2-B40DD5708C2B Q26858933-0094B97F-D675-434F-9AEB-4C69364A3059 Q27010590-0C0275EF-88A9-412D-BB4D-0ADAEF7FE97E Q33579615-F23DF79C-DBA9-4CCE-A3DF-FCE262834CC9 Q33632000-B7AC5414-3276-4ED9-9F7E-ECD42406C640 Q33735039-2BC7F94D-65D2-4280-AB7F-387F05D284DD Q33802284-2ACC2F97-3937-4416-8E33-01ED3C175990 Q34587379-79D105DA-4CC5-4ECF-8506-D9AF8C34C30D Q35740882-3C89B926-7E4A-40AD-9B01-1DB06653F5B2 Q36184067-DE016383-6DB3-4857-A924-9A9C03B41623 Q36236884-7335B3EA-E298-4950-8C8C-477D3DB5D09B Q36940053-36413C7C-ECC3-4B0B-A3F5-0C11FF91C6F1 Q37638759-506400BD-244D-4A6E-93FB-A03F30188572 Q38015162-33A5ABAE-06D8-4EE7-BDAA-DFA480176D62 Q38683309-12E69CAA-D7F5-44F2-9028-BE7B1A12B6F2 Q38690409-260BD36A-219F-411D-B361-4159BB32AE58 Q39022297-93889E50-65E6-43FF-95F6-026AB0C4D478 Q39673688-D5DB4B9C-F0F0-47DE-B70D-D5D00D61EC15 Q40242074-45855065-6E38-47CE-88CF-CE3555C54BEF Q48139808-F62DBCED-896F-4A53-B395-7079A65F7679 Q55249109-2AA05A24-6B33-4700-93FA-1636D4F0553A Q55423757-7A8608CA-C614-4B87-9E55-3CA045DB53CF

P2860

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.

http://www.wikidata.org/entity/Q40326178

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Effect of protracted treatment ...... tients with Cushing's disease.

@en

type

label

Effect of protracted treatment ...... tients with Cushing's disease.

@en

prefLabel

Effect of protracted treatment ...... tients with Cushing's disease.

@en

P1433

Q40326178-1C8B7829-758F-4681-A34A-8DBA1BF87CC7

P1476

Q40326178-550BC660-715B-4933-BA8F-F8C098DC50B4

P2093

Q40326178-0BC32F5C-FEC6-4FE5-AEAB-5E83561D6B35

Q40326178-4EC09073-D8DA-4875-8CEF-DAD5FEC6DB0F

Q40326178-57A57A1B-FE2B-4DD9-A3A1-A19C25BFBE99

Q40326178-59A69E31-8C0C-4547-B622-47593559001C

Q40326178-621B211A-13AD-41CA-972E-3EBD7D1BD3CE

Q40326178-736BF8D7-04AB-447D-8B0F-86FE5A4C9213

Q40326178-82669059-69E0-4182-A2C8-66EE3C21E1AC

Q40326178-CF982DDD-BA48-4787-8364-5CE11921AEB3

Q40326178-E70F9A95-BBFF-49EB-8E45-AEF86E927663

Q40326178-F1239AA5-852F-435A-AD8B-E91CAB7C8437

P2860

Q40326178-02546D0B-B921-4F3A-A504-318E5F3FD3A0

Q40326178-07F5E688-DDC2-49F7-9113-20BFE15499B2

Q40326178-15C3ED43-0B6F-486A-B9E0-3145E62D082E

Q40326178-1C715AAE-1332-4B87-BCE4-771C571E0DC3

Q40326178-1FD40750-B04C-45EC-B3E9-C278C06788B8

Q40326178-37B942A2-3B1B-49FE-AEE8-317987679BCE

Q40326178-3BC93F80-F4CE-4182-AFD8-CF2525051AB1

Q40326178-58CFD62A-D787-471E-BDED-B57CC1D02D28

Q40326178-9680F8CC-B836-474F-9059-D6EFF5E41F14

Q40326178-B1DC3D67-457C-4B02-B39F-497DB5C540AD

P304

Q40326178-A4522D36-E481-45B8-89DD-CADDD5E95740

P31

Q40326178-43719819-BD8A-468A-897B-F833321FA2A4

P356

Q40326178-FB0C7BFC-EED8-4760-AA8D-C5524B565FD4

P433

Q40326178-6CEF4DF6-F20B-4A90-8D74-20CC36A1EDD0

P478

Q40326178-9384687F-C7FB-49A1-8D8C-D0C8B29DBD08

P577

Q40326178-6F9B1BD0-5636-4A2C-8F74-09CF363E6622

P698

Q40326178-6270D7D9-BC55-4233-95C7-D5434A306303

P356

J.1365-2265.2006.02452.X

P1433

Clinical Endocrinology

P1476

Effect of protracted treatment ...... tients with Cushing's disease.

@en

P2093

Adriana A S Leao

http://www.w3.org/2001/XMLSchema#string

Andreea Picu

http://www.w3.org/2001/XMLSchema#string

Carla Scaroni

http://www.w3.org/2001/XMLSchema#string

Emanuela Arvat

http://www.w3.org/2001/XMLSchema#string

Francesca Pecori Giraldi

http://www.w3.org/2001/XMLSchema#string

Francesco Cavagnini

http://www.w3.org/2001/XMLSchema#string

Franco Mantero

http://www.w3.org/2001/XMLSchema#string

Martina Martin

http://www.w3.org/2001/XMLSchema#string

Nora Albiger

http://www.w3.org/2001/XMLSchema#string

Roberta Giordano

http://www.w3.org/2001/XMLSchema#string

P2860

PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.

Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.

Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.

The medical treatment of Cushing's syndrome.

PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.

Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.

Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease.

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.

Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.

P304

219-224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2265.2006.02452.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16430724

http://www.w3.org/2001/XMLSchema#string